A5006871150- Medical Imaging Techniques and Applications
- Genetics and Neurodevelopmental Disorders
- Advanced MRI Techniques and Applications
- Neuroscience and Neuropharmacology Research
- Receptor Mechanisms and Signaling
- Radiomics and Machine Learning in Medical Imaging
- Radiopharmaceutical Chemistry and Applications
- Alzheimer's disease research and treatments
- Parkinson's Disease Mechanisms and Treatments
- Lanthanide and Transition Metal Complexes
- Phosphodiesterase function and regulation
- Neurological disorders and treatments
- Adenosine and Purinergic Signaling
- Neurotransmitter Receptor Influence on Behavior
- Functional Brain Connectivity Studies
- Genetic Neurodegenerative Diseases
- Advanced Neuroimaging Techniques and Applications
- Computational Drug Discovery Methods
- Advanced Radiotherapy Techniques
- Autism Spectrum Disorder Research
- Cholinesterase and Neurodegenerative Diseases
- Pharmacological Receptor Mechanisms and Effects
- Congenital heart defects research
- Drug Transport and Resistance Mechanisms
- Biotin and Related Studies
Commissariat à l'Énergie Atomique et aux Énergies Alternatives
2020-2024
CEA Paris-Saclay
2020-2024
Université Paris-Saclay
2020-2024
Centre National de la Recherche Scientifique
2006-2024
Invicro (United States)
2018-2023
Institute for Neurodegenerative Disorders
2010-2022
Elucid Bioimaging
2012-2021
Clinical Research Institute
2020
CEA Paris-Saclay - Etablissement de Fontenay-aux-roses
2020
Konica Minolta (United States)
2019-2020
Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy. Region-specific tau aggregates establish the neuropathologic diagnosis of definite PSP post mortem. Future interventional trials against in would strongly benefit from biomarkers that support diagnosis.To investigate potential novel radiotracer 18F-PI-2620 as biomarker patients with clinically diagnosed PSP.In this cross-sectional study, participants underwent dynamic positron emission tomography (PET) 0 to 60 minutes after...
<sup>18</sup>F-PI-2620 is a PET tracer with high binding affinity for aggregated tau, key pathologic feature of Alzheimer disease (AD) and other neurodegenerative disorders. Preclinically, binds to both 3-repeat 4-repeat tau isoforms. The purpose this first-in-humans study was evaluate the ability detect pathology in AD patients using imaging, as well assess safety tolerability new tracer. <b>Methods:</b> Participants clinical diagnosis probable healthy controls (HCs) underwent dynamic...
Abstract Several studies have demonstrated that intrastriatal injections of fibrillar α-synuclein in rodent brain induced a Parkinson’s disease-like propagation Lewy body pathology with significant nigrostriatal neurodegeneration. This study evaluated the pathological features when exogenous preformed fibrils were injected into putamen non-human primates. Eight cynomolgus monkeys received unilateral intraputamen and four sham surgery. Monkeys assessed 123I-PE2I single-photon emission...
Abnormal activation of immune system is an important pathogenesis Parkinson's disease, but the relationship between peripheral inflammation, central microglia and dopaminergic degeneration remains unclear.To evaluate brain regional its with clinical severity, presynaptic function, inflammatory biomarkers related to adaptive immunity.In this case-control study, we recruited 23 healthy participants 24 early-stage disease. 18F-PBR06 PET/MR for activation, 18F-FP-DTBZ denervation, total account...
In Huntington disease (HD) striatal neuron loss precedes and predicts motor signs or symptoms.Current imaging biomarkers lack adequate sensitivity for assessing the early stages of HD.Developing an biomarker HD spanning time onset remains a major unmet research need.Intracellular proteins whose expression is altered by mutant huntingtin protein may be superior markers stages.OBJECTIVE To evaluate whether [ 18 F]MNI-659 (2-(2-(3-(4-(2-[...
To evaluate whether striatal [(18)F]MNI-659 PET imaging of phosphodiesterase 10A (PDE10) serves as a sensitive and reliable biomarker neurodegeneration in longitudinal cohort participants with early Huntington disease (HD).A HD, including both premanifest or manifest motor signs, underwent clinical assessments, genetic determination, 2 sessions approximately 1 year apart. Eleven healthy control (HC) assessments once. Striatal binding potentials (BPnd) were estimated for brain regions...
<sup>18</sup>F-AV-1451 is currently the most widely used of several experimental tau PET tracers. The objective this study was to evaluate binding with full kinetic analysis using a metabolite-corrected arterial input function and compare parameters derived from SUV ratio (SUVR) calculated over different imaging time intervals. <b>Methods:</b><sup>18</sup>F-AV-1451 brain completed in 16 subjects: 4 young healthy volunteers (YHV), aged (AHV), 8 Alzheimer disease (AD) subjects. Subjects were...
Abstract Purpose Second-generation tau radiotracers for use with positron emission tomography (PET) have been developed visualization of deposits in vivo. For several β-amyloid and first-generation tau-PET radiotracers, it has shown that early-phase images can be used as a surrogate neuronal injury. Therefore, we investigated the performance early acquisitions novel radiotracer [ 18 F]PI-2620 potential substitute F]fluorodeoxyglucose ([ F]FDG). Methods Twenty-six subjects were referred...
The novel tau-PET tracer [ 18 F]PI-2620 detects the 3/4-repeat-(R)-tauopathy Alzheimer’s disease (AD) and 4R-tauopathies corticobasal syndrome (CBS) progressive supranuclear palsy (PSP). We determined whether binding characteristics deriving from non-invasive reference tissue modelling differentiate 3/4R- 4R-tauopathies. Ten patients with a 3/4R tauopathy (AD continuum) 29 4R (CBS, PSP) were evaluated. PET scans acquired 0-60 min p.i. distribution volume ratio (DVR) was calculated....
To use back-to-back diffusion-weighted imaging (DWI) and PET to obtain quantitative measures of the cerebral metabolic rate oxygen (CMRO(2)) within DWI lesions, assess perfusion-metabolism coupling status by measuring blood flow extraction fraction lesions.Six prospectively recruited acute carotid-territory stroke patients completed protocol, which was commenced 7 21 hours from onset combined derived state-of-the-art diffusion tensor sequencing using a 3-T magnet fully (15)O-PET. The...
Phosphodiesterase (PDE) 10A is an enzyme involved in the regulation of cyclic adenosine monophosphate and guanosine highly expressed medium-sized spiny neurons striatum, making it attractive target for novel therapies a variety neurologic psychiatric disorders that involve striatal function. Potential ligands PET imaging PDE10A have been reported. Here, we report first-in-human characterization 2 new radioligands,...
PET with selective adenosine 2A receptor (A2A) radiotracers can be used to study a variety of neurodegenerative and neuropsychiatric disorders in vivo support drug-discovery studies targeting A2A. The aim this was describe the first evaluation (18)F-MNI-444, novel radiotracer for imaging A2A, healthy human subjects.Ten volunteers were enrolled study; 6 completed brain 4 participated whole-body studies. Arterial blood collected invasive kinetic modeling data. Noninvasive methods data...
The P2X7 receptor is an adenosine triphosphate–gated ion channel, which abundantly expressed in glial cells within the central nervous system and periphery. activation leads to release of proinflammatory cytokine IL-1β brain, antagonism a novel therapeutic strategy dampen triphosphate–dependent signaling. PET ligands for will not only be valuable assess target engagement drug candidates but also hold promise as surrogate markers neuroinflammation. Herein we describe vitro vivo evaluation...
Our aim was to synthesise an 18 F analogue of endothelin‐1 (ET‐1), dynamically image ET receptors in vivo by positron emission tomography (PET) and elucidate the function B subtype as a clearing receptor organs expressing high densities including kidney lung. [ F]‐ET‐1 characterised vitro bound with single subnanomolar affinity ( K D =0.43±0.05 n M , max =27.8±2.1 fmol mg −1 protein) human left ventricle =4). The distribution anaesthetised rats measured using dedicated small animal PET...
Stroke-like Migraine Attacks after Radiation Therapy (SMART) syndrome is a rare complication of cranial irradiation. well-known to impair vascular vessel architecture and function. We investigated the hypothesis radiation-induced cerebral reserve dysfunction as underlying mechanism SMART. Interictal cerebrovascular reactivity was using Tc-99m hexamethylpropyleneamine oxime-SPECT acetazolamide challenge in 3 patients. found interictal hypoperfusion normal all Neither ictal restriction...
Non-invasive imaging of amyloid-β in the brain, a hallmark Alzheimer’s disease, may support earlier and more accurate diagnosis disease. In this study, we assessed novel single photon emission computed tomography tracer 123 I-ABC577 as potential biomarker for brain. The radio-iodinated imidazopyridine derivative was designed candidate agent. binding affinity evaluated by saturation assay vitro autoradiography using post-mortem disease brain tissue. Biodistribution experiments normal rats...
Motor symptoms in Parkinson disease (PD) are caused by a loss of dopamine input from the substantia nigra to striatum. Blockade adenosine 2A (A(2A)) receptors facilitates D(2) receptor function. In phase 2 clinical trials, A(2A) antagonists (istradefylline, preladenant, and tozadenant) improved motor function PD. We developed new PET radiotracer, (18)F-MNI-444, used it investigate relationship between plasma levels occupancy preladenant tozadenant nonhuman primates (NHP).A series 20...
Abstract Background As a biomarker targeting vesicular monoamine transporter 2 (VMAT2), 18 F‐9‐fluoropropyldihydrotetrabenazine ( F‐FP‐DTBZ) positron emission tomography (PET) is highly accurate in diagnosing Parkinson's disease (PD) and assessing its severity. However, evidence insufficient patients with progressive supranuclear palsy (PSP). Objective We evaluated the striatal extrastriatal monoaminergic disruption of PSP differences patterns between PSP, PD, healthy controls (HCs) using...
For Monte Carlo simulations to be used as an alternative solution perform scatter correction, accurate modelling of the scanner well speed is paramount. General-purpose packages (Geant4, EGS, MCNP) allow a detailed description but are not efficient at simulating voxel-based geometries (patient images). On other hand, dedicated codes (SimSET, PETSIM) will for objects poor in their capacity complex such PET scanner. The approach adopted this work was couple code (SimSET) with general-purpose...